Faculty Members

Sandy McEwan

Professor and Chair, Department of Oncology
Member, Canadian Nuclear Safety Commission
Oncologic Imaging
Department of Oncology
University of Alberta
Cross Cancer Institute
11560 University Avenue
Edmonton, Alberta T6G 1Z2

Tel: 780.432.8524


Research Interests

Radioisotope therapy     
     131I mIBG and 111In Octreotide
     131I ERC9
     Unsealed source therapy: mechanisms of effect

Novel radiopharmaceutical development 

Molecular Imaging and Clinical Trial Design                   

      Imaging biomarkers
      Treatment stratification and treatment planning
      Assays of response
Hypoxia Imaging
MD in Preparation: Radioisotope Therapy: Reflections on Effectiveness Mechanisms of Action and Future Clinical Needs.

Dr. Alexander (Sandy) McEwan was appointed as member of the Canadian Nuclear Safety Commission on March 7, 2013.





Drever L, Robinson DM, McEwan AJB, Roa W. A Local Contrast Based Approach to Threshold Segmentation for PET Target Volume Delineation. Medical Physics 2006; 33(6):1583-1594.

Gulenchyn KY, McEwan AJ, Freeman M, Kiess M, O'Neill BJ, Beanlands RS, CANM, CSS. Treating the right patient at the right time: access to cardiovascular nuclear imaging. Can J Cardiol 2006; 22(1):827-833.

Alexander A, Murtha A, Abdulkarim B, Mehta V, Wheatley M, Murray B, Riauka T, Hanson J. Fulton D, McEwan A, Roa W. Prognostic significance of serial magnetic resonance spectroscopies over the course of radiation therapy for patients with malignant glioma. Clin Invest Med 2006; 29(5):301-311.

Sandler MP, McEwan AJ. Revoluntionizing the Future. RT Image 2006; 19(45). (



Murray D and McEwan AJ. Radiobiology of Systemic Radiation Therapy. Cancer Biotherapy and Radiopharmaceuticals 2007, 22(1):1-23.

Kennedy A, Nag S, Salem R, Murthy R, McEwan AJ, Nutting C, Benson A, Espat J, Bilbao JI, Sharma RA, Thomas JA, Coldwell D. Recommendations for Radioembolization of Hepatic Malignancies Using Yttrium-90 (Y90) Microsphere Brachytherapy: A Consensus Panel Report from the Radioembolization Brachytherapy Oncology Consortium (REBOC). Int J Rad Oncol Biol Phys 2007; 68(1):13-23.

Demeter S, Jacobs P, Chmielowiec C, Logus W, Hailey D, Fassbender K, McEwan AB. The Cost of Lung Cancer in Alberta. Can Resp J 2007; 14(2):81-86.

Joshua A, Sharma SK, Strelkov A, Scott JR, Martin-Iverson MT, Abrams DN, Silverstone PH, McEwan AJB. Synthesis and Biodistribution of 8-Iodo-11-(4-methylpiperazino)-5H-dibenzo[b,e][1,4]-diazepine: Iozapine. Bioorg Med Chem Lett 2007; 17: 4066-4069.

Drever L, Roa W, McEwan A, Robinson D. Comparison of three image segmentation techniques for target volume delineation in positron emission tomography. J Appl Clin Med Phys 2007; 8(2): 93-109.

Drever L, Roa W, McEwan A, Robinson D. Iterative threshold segmentation for PET target volume delineation. Med Phys 2007; 34(4): 1253-1265.

McEwan AJB. SNM Leadership Update: Molecular Imaging…Realistically…An Evolution in Nuclear Medicine Practice. J Nucl Med, 2007; 48(8): 31N, 38N.

McEwan AJB. How Do We Introduce the Next Generation of Radiotracers into Clinical Practice? SNM Leadership Update, J Nucl Med, 2007; 48(9): 28N, 30N.

Kumar P, Mercer, J, Doerksen C, Tonkin K, McEwan AJB. Clinical production, stability studies and PET imaging with 16--[18F]fluoroestradiol ([18F]FES) in ER positive breast cancer patients. J Pharm Pharmaceut Sci, 2007; 10(2); 256s-265s.

Emami S, Kumar P, Yang J, Kresolek Z, Paproski R, Cass C, McEwan AJB, Wiebe LI. Synthesis, transport and hypoxia-selective binding of 1--D-(5-deoxy-5-fluororibofuranosyl)-2-nitroimidazole (-5-FAZR), a configurational isomer of the clinical hypoxia marker, FAZA. J Pharm Pharmaceut Sci, 2007; 10(2): 237-245.

McEwan AJB. SNM Leadership Update: Funding Nuclear Medicine Research. J Nucl Med, 2007; 48(11); 23N.

McEwan AJB. Radiation Rules are Strict. Letter. USA Today, November 28, 2007.

McEwan AJB. SNM Leadership Update: Advocating for PET/CT. J Nucl Med, 2007; 48(12): 26N.



McEwan AJB. Continuing and Accumulating Successes. J. Nucl Med 2008; 49(2): 16N-18N.
Kumar P, Emami S, McEwan AJB, Wiebe LI. Stereospecific deuteration of -furanosyl azomycin nucleosides; a model reaction for tritium radiolabeling. Bioorganic & Medicinal Chemistry Letters, 2008; 18(11):3256-3260.
McEwan AJB, Van Brocklin HF, Divgi C. Action Plan for Emerging Molecular Imaging Technologies. JNM White Paper. J Nucl Med 2008; 49(2):37N-41N.
Sandha GS, Severin D, Postema E, McEwan A, Stewart K. Is positron emission tomography useful in locoregional staging of esophageal cancer? Results of a multidisciplinary initiative comparing CT, positron emission tomography and EUS. Gastrointest Endosc, 2008; 67(3):402-409.
McEwan AJB. SNM Leadership Update: A Look Back at a Year of Extraordinary Success and Forward to a Rewarding Future. J Nucl Med, 2008; 49(6): 80N-81N.
Conti PS, McEwan AJB, Pomper MG. SNM Newsline: Molecular Imaging: The Future of Modern Medicine. J Nucl Med, 2008; 49(6):16N-20N.
Kong T, Zeng J, Wang X, Yang X, Yang J, McQuarrie S, McEwan A, Roa W, Chen J, Xing JZ. Enhancement of radiation cytotoxicity in breast-cancer cells by localized attachment of gold nanoparticles. Small, 2008; 4(9):1537-1543.
Sharma SK, Zheng W, Joshua AV, Abrams DN, McEwan AJB. Synthesis and Evaluation of Novel 4-amino-4,6-androstadiene-3,17-dione: An Analog of Formestane. Bioorganic & Medicinal Chemistry Letters, 2008; 18(20): 5563-5566.
Graham MM and McEwan AJB. Therapeutic Pharmaceutical Developers Join with SNM and Molecular Imaging via the Clinical Trials Network. MI Gateway—Newsletter of the Society of Nuclear Medicine Molecular Imaging Center of Excellence, 2009; Special Issues: 1-5.
Christian PE, Graham MM, McEwan AJB. The Phantom Program—A Roundtable Discussion with Paul Christian, Michael Graham and Alexander McEwan. MI Gateway—Newsletter of the Society of Nuclear Medicine Molecular Imaging Center of Excellence, 2009; Special Issues: 4-5.
Suchak AA, Millo N, MacEwan R, McEwan AJB. Neuroendocrine Differentiated Breast Carcinoma with Pleural Metastases Using Indium-111 Octreotide. Clin Nucl Med, 2009; 34:74-75.
McEwan A, Graham MM, Conti PS. SNM Newsline: SNM Molecular Imaging Summit Introduces Clinical Trials Network. J Nucl Med, 2009; 50(4):18N.
Postema EJ, McEwan AJB, Riauka TA, Kumar P, Richmond DA, Abrams DN, Wiebe LI. Initial Results of Hypoxia Imaging Using 1--D-(5-deoxy-5-[18F]-fluoroarabinofuranosyl)-2-nitroimidazole (18F-FAZA). Eur J Nucl Med Mol Imaging, 2009; 36: 1565-1573.
Postema EJ and McEwan AJB. Radioiodinated Metaiodobenzylguanidine Treatment of Neuroendocrine Tumors in Adults. Cancer Biotherapy and Radiopharmaceuticals, 2009; 24(5): 519-525.
Kumar P, Emami S, Kresolek Z, Yang J, McEwan AJ, Wiebe LI. Synthesis and hypoxia selective radiosensitization potential of beta-2-FAZA and beta-3-FAZL: fluorinated azomycin beta-nucleosides. Med Chem, 2009; 5(2):118-129.
McEwan AJB, Graham MM, Conti PS. Site Qualification in Multicenter Clinical Trials. J Nucl Med, 2009; 50(8): 30N.
Kerhet A, Small C, Quon H, Riauka T, Schrader L, Greiner R, Yee D, McEwan A, Roa W. Application of Machine Learning Methodology for PET-Based Definition of Lung Cancer. Current Oncology, 2010, 17(1): 41-43.
Kumar P, Naimi E, McEwan AJ, Wiebe LI. Synthesis, Radiofluorination, and Hypoxia-selective Studies of FRAZ: A Configurational and Positional Analogue of the Clinical Hypoxia Marker [18F]-FAZA. Bioorg Med Chem, 2010; 18(6):2255-2264.
Paproski RJ, Wuest M, Jans HS, Graham K, Gati WP, McQuarrie S, McEwan A, Mercer J, Young JD, Cass CE. Biodistribution and uptake of 3’-deoxy-3’-fluorothymidine in ENT1-knockout mice and in an ENT1-knockdown tumor model. J Nucl Med, 2010; 51(9):1447-55.
AA El-Mabhouh, PN Nation, JT Abele, T Riauka, E. Postema, AJB McEwan, JR Mercer. A Conjugate of Gemcitabine with Bisphosphonate (Gem/BP) Shows Potential as a Targeted Bone-Specific Therapeutic Agent in an Animal Model of Human Breast Cancer Bone Metastases. Onc. Res., 2011; Vol 9:1-100.
Wuest M, Trayner BJ, Grant TN, Jans HS, Mercer JR, Murray D, West FG, McEwan AJB, Wuest F, Cheeseman CI. Radiopharmacological evaluation of 6-deoxy-6-[18F]fluoro-D-fructose as a radiotracer for PET imaging of GLUT5 in breast cancer. Nucl Med Biol. May 2011;38(4):(461-75).
Gagnon K, McQuarrie S, Abrams D, McEwan AJB, Wuest F. Radiotracers Based on Technetium-94m Current Radiopharmaceuticals. 2011;4:(90-101)